Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
81.77
+0.24 (+0.29%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dr. Reddy's Laboratories Ltd ADR
< Previous
1
2
3
Next >
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
July 29, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1FY25 Financial Results
July 27, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
June 26, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
June 03, 2024
From
Aurigene Pharmaceutical Services Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
May 28, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
May 07, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
May 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
March 19, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q3 & 9M FY24 Financial Results
January 31, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
January 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
December 14, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Dr. Reddy’s Q2 FY24 Financial Results
October 27, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
August 10, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1 FY24 Financial Results
July 26, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
July 12, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Drugmaker GSK: Becoming a Healthier Value Stock
June 27, 2023
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
June 05, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q4 & FY23 Financial Results
May 10, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
May 05, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
April 21, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session
April 12, 2023
Via
Investor Brand Network
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session
April 10, 2023
Via
Investor Brand Network
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
By Kenneth Adams, Benzinga
Via
TheNewswire.com
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
March 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.